Facilitators and barriers in anorexia nervosa treatment initiation (FABIANA): study protocol for a mixed-methods and multicentre study.
Anorexia nervosa
duration of untreated illness
early intervention
facilitators and barriers
psychotherapy
Journal
BJPsych open
ISSN: 2056-4724
Titre abrégé: BJPsych Open
Pays: England
ID NLM: 101667931
Informations de publication
Date de publication:
21 Oct 2019
21 Oct 2019
Historique:
entrez:
22
10
2019
pubmed:
22
10
2019
medline:
22
10
2019
Statut:
epublish
Résumé
Anorexia nervosa is a serious disorder, which often takes a chronic course. Early treatment leads to a significantly better prognosis and prevents chronicity. However, existing evidence on facilitators and barriers in anorexia nervosa treatment initiation is scarce. Against this background, the FABIANA study (ClinicalTrials.gov Identifier: NCT03713541) aims to (a) identify potentially modifiable facilitators and barriers from the perspectives of adolescent and adult patients with anorexia nervosa, carers and physicians, (b) develop and test an instrument for the combined assessment of multiple key facilitators and barriers, and (c) quantify the effect of potentially modifiable versus non-modifiable key facilitators and barriers on the duration of untreated illness (DUI) in patients with anorexia nervosa. FABIANA is an observational, mixed-method-study divided into three consecutive substudies each corresponding to one of the study aims. All three substudies will include female patients with anorexia nervosa aged 14 years and older at the beginning of their first psychotherapeutic anorexia nervosa treatment. The qualitative substudy I and the quantitative substudy III will additionally include carers and involved physicians. The recruitment will take place at 20 cooperating study centres throughout Germany, which provide in-patient or out-patient anorexia nervosa specialist care. The DUI will be calculated based on the month of illness onset as determined in validated interviews on lifetime anorexia nervosa symptoms and the therapist-reported date of treatment initiation. Strengths and limitations of the retrospective assessment of the DUI will be discussed. The findings of the FABIANA study will contribute to the development of evidence-based early-intervention approaches and the prevention of a chronic course of illness. ClinicalTrials.gov Identifier: NCT03713541. None.
Sections du résumé
BACKGROUND
BACKGROUND
Anorexia nervosa is a serious disorder, which often takes a chronic course. Early treatment leads to a significantly better prognosis and prevents chronicity. However, existing evidence on facilitators and barriers in anorexia nervosa treatment initiation is scarce.
AIMS
OBJECTIVE
Against this background, the FABIANA study (ClinicalTrials.gov Identifier: NCT03713541) aims to (a) identify potentially modifiable facilitators and barriers from the perspectives of adolescent and adult patients with anorexia nervosa, carers and physicians, (b) develop and test an instrument for the combined assessment of multiple key facilitators and barriers, and (c) quantify the effect of potentially modifiable versus non-modifiable key facilitators and barriers on the duration of untreated illness (DUI) in patients with anorexia nervosa.
METHOD
METHODS
FABIANA is an observational, mixed-method-study divided into three consecutive substudies each corresponding to one of the study aims. All three substudies will include female patients with anorexia nervosa aged 14 years and older at the beginning of their first psychotherapeutic anorexia nervosa treatment. The qualitative substudy I and the quantitative substudy III will additionally include carers and involved physicians. The recruitment will take place at 20 cooperating study centres throughout Germany, which provide in-patient or out-patient anorexia nervosa specialist care. The DUI will be calculated based on the month of illness onset as determined in validated interviews on lifetime anorexia nervosa symptoms and the therapist-reported date of treatment initiation.
CONCLUSIONS
CONCLUSIONS
Strengths and limitations of the retrospective assessment of the DUI will be discussed. The findings of the FABIANA study will contribute to the development of evidence-based early-intervention approaches and the prevention of a chronic course of illness.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov Identifier: NCT03713541.
DECLARATION OF INTEREST
BACKGROUND
None.
Identifiants
pubmed: 31631825
doi: 10.1192/bjo.2019.77
pii: S2056472419000772
pmc: PMC6854360
doi:
Banques de données
ClinicalTrials.gov
['NCT03713541']
Types de publication
Journal Article
Langues
eng
Pagination
e92Références
Int J Eat Disord. 2016 Jun;49(6):630-4
pubmed: 26841271
Pediatrics. 2012 Feb;129(2):e438-46
pubmed: 22218841
Evid Based Ment Health. 2018 Nov;21(4):182-184
pubmed: 30352884
Curr Opin Psychiatry. 2016 Nov;29(6):340-5
pubmed: 27662598
Value Health. 2015 Jan;18(1):110-5
pubmed: 25595241
Z Kinder Jugendpsychiatr Psychother. 2008 Mar;36(2):117-25
pubmed: 18622941
Int J Eat Disord. 2017 Nov;50(11):1255-1263
pubmed: 28963857
Fam Pract. 2009 Feb;26(1):65-8
pubmed: 19074758
Int J Eat Disord. 2014 Jul;47(5):507-15
pubmed: 24599787
Psychol Med. 2009 Jan;39(1):105-14
pubmed: 18377676
Lancet. 2007 Oct 20;370(9596):1453-7
pubmed: 18064739
Psychiatr Prax. 2019 Sep;46(6):342-348
pubmed: 31284318
Int J Eat Disord. 2017 Jan;50(1):9-21
pubmed: 27526643
Early Interv Psychiatry. 2018 Apr;12(2):250-257
pubmed: 27619198
Future Child. 1999 Fall;9(2):30-44
pubmed: 10646256
Eur Eat Disord Rev. 2014 Jul;22(4):292-8
pubmed: 24888519
Eat Disord. 2017 Jan-Feb;25(1):1-21
pubmed: 27485375
Br J Clin Psychol. 2006 Sep;45(Pt 3):343-66
pubmed: 17147101
Int J Eat Disord. 2017 Sep;50(9):1018-1030
pubmed: 28644530
Lancet Psychiatry. 2015 Dec;2(12):1099-111
pubmed: 26514083
Psychosoc Med. 2012;9:Doc11
pubmed: 23133505
Int J Eat Disord. 2017 Mar;50(3):190-209
pubmed: 28134980
Int J Qual Health Care. 2007 Dec;19(6):349-57
pubmed: 17872937
Curr Opin Psychiatry. 2018 Nov;31(6):445-455
pubmed: 30113325
Ann Intern Med. 2015 Jan 6;162(1):55-63
pubmed: 25560714
Lancet. 2000 Feb 26;355(9205):721-2
pubmed: 10703806
Int J Eat Disord. 2017 Jun;50(6):679-686
pubmed: 28122128
J Health Econ. 2014 May;35:34-46
pubmed: 24595066
Int J Eat Disord. 2016 Jun;49(6):613-6
pubmed: 26711183
Int J Eat Disord. 2015 Jan;48(1):139-46
pubmed: 24634140
Soc Psychiatry Psychiatr Epidemiol. 2018 Oct;53(10):1005-1038
pubmed: 30136192
Early Interv Psychiatry. 2012 Nov;6(4):357-67
pubmed: 22759660
Am J Psychiatry. 2002 Aug;159(8):1284-93
pubmed: 12153817
Clin Psychol Rev. 2011 Jul;31(5):727-35
pubmed: 21501580
Curr Opin Psychiatry. 2013 Nov;26(6):543-8
pubmed: 24060914
Psychol Med. 2001 Jul;31(5):881-90
pubmed: 11459385
Psychopathology. 2013;46(1):14-21
pubmed: 22890286